Cannabidiol Oral Solution [Epidiolex]
ApprovedActive 0 watching 0 views this week🔥 Hot
82
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Tuberous Sclerosis Complex Associated Neuropsychiatric Disease
Conditions
Tuberous Sclerosis Complex Associated Neuropsychiatric Disease
Trial Timeline
Jun 29, 2023 → Mar 26, 2026
NCT ID
NCT05864846About Cannabidiol Oral Solution [Epidiolex]
Cannabidiol Oral Solution [Epidiolex] is a approved stage product being developed by Jazz Pharmaceuticals for Tuberous Sclerosis Complex Associated Neuropsychiatric Disease. The current trial status is active. This product is registered under clinical trial identifier NCT05864846. Target conditions include Tuberous Sclerosis Complex Associated Neuropsychiatric Disease.
Hype Score Breakdown
Clinical
30
Activity
20
Company
7
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05864846 | Approved | Active |
Competing Products
13 competing products in Tuberous Sclerosis Complex Associated Neuropsychiatric Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Everolimus (RAD001) + Everolimus Placebo | Novartis | Phase 3 | 77 |
| Everolimus + Placebo | Novartis | Phase 3 | 77 |
| RAD001 | Novartis | Phase 1/2 | 41 |
| Placebo + Everolimus (RAD001) | Novartis | Phase 2 | 52 |
| RAD001 + Placebo | Novartis | Phase 2 | 52 |
| RAD001 + Placebo + Antiepileptic drug (1 to 3 only) + open label RAD001 (only used for post-extension phase) | Novartis | Phase 3 | 77 |
| Everolimus | Novartis | Phase 1/2 | 41 |
| everolimus (RAD001) | Novartis | Phase 1/2 | 41 |
| everolimus | Novartis | Phase 3 | 77 |
| sirolimus | Pfizer | Phase 2 | 51 |
| GWP42003-P | Jazz Pharmaceuticals | Phase 3 | 74 |
| GWP42003-P | Jazz Pharmaceuticals | Phase 3 | 74 |
| GWP42003-P + Placebo | Jazz Pharmaceuticals | Phase 3 | 74 |